51
|
Gabor F, Haberl I, Wirth M, Richter K, Theyer G, Baumgartner G, Wenzl E, Hamilton G. In vitro antitumor activity of MIC2 protein-doxorubicin conjugates. Int J Oncol 2012; 9:527-31. [PMID: 21541546 DOI: 10.3892/ijo.9.3.527] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The pseudoautosomal encoded MIC2 glycoprotein is a tumor-associated antigen of Ewing's sarcoma (ES) and closely related tumors of unknown function. To investigate the use of this protein as selective drug carrier recombinant MIC2 was coupled to doxorubicin by a two step glutaraldehyde method (molar ratio DOX/MIC2 of 32 and 16). The conjugates showed dose-dependent cytostatic activity against the ES cell line SK-ES1, the peripheral neuroectodermal line KAL and the prostate cancer cell line PC-3 concurrent with reduced toxicity against normal lymphoblasts. In comparison to free doxorubicin the MIC2-doxorubicin conjugates exhibited highest activity against the PC-3 cell line. Confocal microscopy showed intracellular accumulation of MIC2 conjugates.
Collapse
|
52
|
Lannert H, Heidenreich A, Gschwend J, Gil T, Zastrow S, Laniado M, Zühlsdorf M, Gerloff J, Uhl W, Wirth M. A Phase 1 Study of EMD 525797 (DI17E6), A Humanized Monoclonal Antibody to Human AV Integrins, in CRPC with Bone Metastases After Chemotherapy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)31972-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
53
|
Chapple CR, Montorsi F, Tammela TLJ, Wirth M, Koldewijn E, Fernandez Fernandez E. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe]. UROLOGIIA (MOSCOW, RUSSIA : 1999) 2012:38-45. [PMID: 23342615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Silodosin is a new selective therapy with a high pharmacologic selectivity for the a (1A)-adrenoreceptor. OBJECTIVE Our aim was to test silodosin's superiority to placebo and noninferiority to tamsulosin and discuss the findings in the context of a comprehensive literature review of the new compound silodosin. DESIGN, SETTING, AND PARTICIPANTS We conducted a multicenter double-blind, placebo-and active-controlled parallel group study. A total of 1228 men > or = 50 yr of age with an International Prostate Symptom Score (IPSS) < or = 13 and a urine maximum flow rate (Q(max))> 4 and < or = 15 ml/s were selected at 72 sites in 11 European countries. The patients were entered into a 2-wk wash-out and a 4-wk placebo run-in period. A total of 955 patients were randomized (2:2:1) to silodosin 8 mg (n = 381), tamsulosin 0.4 mg (n = 384), or placebo (n = 190) once daily for 12 wk. MEASUREMENTS We calculated the change from baseline in IPSS total score (primary), storage and voiding subscores, quality of life (QoL) due to urinary symptoms, and Q(max). Responders were defined on the basis of IPSS and Q(max) by a decrease of > or = 25% and an increase of > or = 30% from baseline, respectively. RESULTS AND LIMITATIONS The change from baseline in the IPSS total score with silodosin and tamsulosin was significantly superior to that with placebo (p < 0.001): difference active placebo of -2.3 (95% confidence interval [CI], -3.2, -1.4) with silodosin and -2.0 (95% CI, -2.9, -1.1) with tamsulosin. Responder rates according to total IPSS were significantly higher (p < 0.001) with silodosin (66.8%) and tamsulosin (65.4%) than with placebo (50.8%). Active treatments were also superior to placebo in the IPSS storage and voiding subscore analyses, as well as in QoL due to urinary symptoms. Of note, only silodosin significantly reduced nocturia versus placebo (the change from baseline was -0.9, -0.8, and -0.7 for silodosin, tamsulosin, and placebo, respectively; p = 0.013 for silodosin vs placebo). An increase in Q(max) was observed in all groups. The adjusted mean change from baseline to end point was 3.77 ml/s for silodosin, 3.53 ml/s for tamsulosin, and 2.93 ml/s for placebo, but the change for silodosin and tamsulosin was not statistically significant versus placebo because of a particularly high placebo response (silodosin vs placebo: p = 0.089; tamsulosin vs placebo: p = 0.221). At end point, the percentage of responders by Q(max) was 46.6%, 46.5%, and 40.5% in the silodosin, tamsulosin, and placebo treatment groups, respectively. This difference was not statistically significant (p = 0.155 silodosin vs placebo and p = 0.141 tamsulosin vs placebo). Active treatments were well tolerated, and discontinuation rates due to adverse events were low in all groups (2.1%, 1.0%, and 1.6% with silodosin, tamsulosin, and placebo, respectively). The most frequent adverse event with silodosin was a reduced or absent ejaculation during orgasm (14%), a reversible effect as a consequence of the potent and selective a(1A)-adrenoreceptor antagonism of the drug. The incidence was higher than that observed with tamsulosin (2%); however, only 1.3% of silodosin-treated patients discontinued treatment due to this adverse event. CONCLUSIONS Silodosin is an effective and well-tolerated treatment for the relief of both voiding and storage symptoms in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction thought to be associated with benign prostatic hyperplasia. Its overall efficacy is not inferior to tamsulosin. Only silodosin showed a significant effect on nocturia over placebo.
Collapse
|
54
|
Wirth M, Stojanovic N, Christian J, Henkel L, Paul M, Schmid R, Hacker G, Saur D, Schneider G. 135 MYC Controls Transcription of NOXa and BIM to Trigger Apoptosis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70835-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
55
|
Kunze D, Kraemer K, Fuessel S, Grimm M, Wirth M. MP-04.17 Simultaneous siRNA-Mediated Inhibition of Antiapoptotic BCL2, BCL2L1, Survivin and XIAP in Different Bladder Cancer Cell Lines. Urology 2011. [DOI: 10.1016/j.urology.2011.07.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
56
|
Froehner M, Schober R, Koch R, Lossnitzer A, Wirth M. UP-03.001 Adult Urological Sarcomas: 20-Year Experience. Urology 2011. [DOI: 10.1016/j.urology.2011.07.1091] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
57
|
Erdmann K, Thomae C, Scholze J, Kraemer K, Sergon M, Froehner M, Fuessel S, Wirth M. MP-13.20 Diminished Expression of Selected Micrornas Correlates with Up-Regulation of Prostate Cancer Associated Genes. Urology 2011. [DOI: 10.1016/j.urology.2011.07.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
58
|
Wirth M, Heidenreich A, Gschwend J, Gil T, Zastrow S, Laniado M, Bernard L, Vardar T, Uhl W, Lannert H. 7013 POSTER DISCUSSION A Phase 1 Study of DI17E6, an Antibody Targeting AV Integrins, in Progressive Castrate-resistant Prostate Cancer With Bone Metastases (mCRPC) After Chemotherapy. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71964-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
59
|
Weissflog C, Oehlschlaeger S, Wirth M. MP-10.03 Evaluation of Risk Factors for Prognosis of Temporary Renal Impairment After Secondary Extracorporeal Shock Wave Lithotripsy (ESWL) in Renal Stone Treatment. Urology 2011. [DOI: 10.1016/j.urology.2011.07.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
60
|
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. Int Braz J Urol 2011. [DOI: 10.1590/s1677-55382011000300021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
61
|
Saad F, Akaza H, Eisenberger MA, Nelson J, Scher HI, Suzuki K, Wirth M, Webb IJ, Wang J, MacLean D, De Wit R. A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps184] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
62
|
Wirth M, Heidenreich A, Gschwend JE, Gil T, Zastrow S, Laniado M, Bernard L, Vardar T, Uhl W, Lannert H. A multicenter phase I study of DI17E6, a novel de-immunized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer (CRPC) with bone metastases after chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
63
|
Abstract
Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.
Collapse
|
64
|
Horn H, Jann K, Walther S, Federspiel A, Wirth M, Müller T, Strik W. Thought disorder: a left lateralised breakdown of the language network. Eur Psychiatry 2011. [DOI: 10.1016/s0924-9338(11)73105-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
IntroductionStructural and functional deviations in schizophrenic patients with formal thought disorder (FTD) point towards a dysfunction within left sided language network.ObjectivesIndependent component analysis (ICA), a new approach to fMRI analysis, enables to target the question of a network dysfunction directly. Using this method in healthy controls it was possible to identify the language networks separately for the left and the right hemispheres In the present study we use ICA analysis to examine changes of the language network separate for each hemisphere in relation to the severity of FTD.AimsWe hypothesize increasing disintegration with increasing severity of FTD only in the left sided language network while the right language network should remain unaffected.MethodsWe investigated 16 schizophrenic patients with different severity of FTD and matched healthy controls using ICA decomposition of the BOLD signal. The spatial similarity of the individual language networks was correlated to the severity of FTD.ResultsThe integrity of the left language network decrease with increasing severity of FTD (r = -0.79, p < 0.01), while the integrity of the right language network show no significant correlation to the severity of FTD.ConclusionFor the first time the isolated breakdown of the left sided language network was linked specifically to schizophrenic FTD. This result unites older manly left hemispheric findings of structural and functional abnormalities in schizophrenic FTD.
Collapse
|
65
|
Jandt U, Shao S, Binius S, Wirth M, Zeng A. Spatiotemporal Modeling of Transient Transfection Processes in Mammalian Cell Culture. CHEM-ING-TECH 2010. [DOI: 10.1002/cite.201050184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
66
|
Abrahamsson P, Artibani W, Chapple C, Wirth M. Asociación Europea de Urología. Declaración de postura sobre el cribado del cáncer prostático. Actas Urol Esp 2010. [DOI: 10.1016/j.acuro.2010.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
67
|
Abrahamsson PA, Artibani W, Chapple CR, Wirth M. [European Association of Urology. Position statement on screening for prostate cancer]. Actas Urol Esp 2010; 34:221-222. [PMID: 20416237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
68
|
Abrahamsson P, Artibani W, Chapple C, Wirth M. Asociación Europea de Urología: Declaración de postura sobre el cribado del cáncer prostático. Actas Urol Esp 2010. [DOI: 10.4321/s0210-48062010000300001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
69
|
Plattner VE, Germann B, Neuhaus W, Noe CR, Gabor F, Wirth M. Characterization of two blood-brain barrier mimicking cell lines: distribution of lectin-binding sites and perspectives for drug delivery. Int J Pharm 2009; 387:34-41. [PMID: 19963051 DOI: 10.1016/j.ijpharm.2009.11.030] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Accepted: 11/28/2009] [Indexed: 11/16/2022]
Abstract
In the present study plant lectins with distinct sugar specificities were applied to two blood-brain barrier (BBB) mimicking cell lines, namely human ECV304 and porcine brain microvascular endothelial cells PBMEC/C1-2 in order to elucidate their glycosylation pattern and to evaluate the lectin-cell interaction for lectin-mediated targeting. The bioadhesive properties of fluorescein-labeled lectins were investigated with monolayers as well as single cells using fluorimetry and flow cytometry, followed by confirmation of the specificity of binding. For PBMEC/C1-2 layers highest binding capacity was found for wheat germ agglutinin (WGA), followed by Dolichus biflorus agglutinin (DBA) whereas single cell experiments revealed a predominance of DBA only. Analyzing ECV304 monolayers and single cells, WGA yielded the strongest interaction without any changes during cultivation. The binding capacities of the other lectins increased significantly during differentiation. As similar results to primary cells and brain sections were observed, both cell lines seem to be suitable as models for lectin-interaction studies. Thus, an additional focus was set on the mechanisms involved in uptake and intracellular fate of selected lectins. Cytoinvasion studies were performed with WGA for human ECV304 cells and WGA as well as DBA for PBMEC/C1-2 cells. For both lectins, the association rate to the cells was dependent on temperature which indicated cellular uptake.
Collapse
|
70
|
Plattner VE, Ratzinger G, Engleder ET, Gallauner S, Gabor F, Wirth M. Alteration of the glycosylation pattern of monocytic THP-1 cells upon differentiation and its impact on lectin-mediated drug delivery. Eur J Pharm Biopharm 2009; 73:324-30. [PMID: 19602437 DOI: 10.1016/j.ejpb.2009.07.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2009] [Revised: 06/29/2009] [Accepted: 07/08/2009] [Indexed: 11/26/2022]
Abstract
In the present study, human monocytic THP-1 cells were treated with phorbol-12-myristate-13-acetate (PMA) in order to obtain macrophage-like cells. Before and after treatment, plant lectins with distinct sugar specificities were applied in order to elucidate the glycosylation patterns of both monocytic and macrophage-like cell types and to follow changes during differentiation. As a result of flow-cytometric analyses, for untreated as well as for PMA-differentiated cells WGA yielded the highest binding rate without significant changes in the binding capacity. For the other lectins, divergent results were obtained which point to reorganization of sugar residues on the cell surface during differentiation. Additionally, cytoinvasion being beneficial for enhanced drug absorption was studied with WGA which had displayed a high binding capacity together with a high specificity. For both untreated and PMA-differentiated cells decreased fluorescence intensity at 37 degrees C as compared to 4 degrees C was observable pointing to internalization and accumulation within acidic compartments. Moreover, WGA-functionalized PLGA nanoparticles were prepared, and their uptake evaluated. Uptake rates of 55% in case of PMA-differentiated cells suggested that WGA-grafted drug delivery systems might be an interesting approach for treatment of infectious diseases provoked by parasites, facultative intracellular bacteria, or viruses such as HIV.
Collapse
|
71
|
Wirth M, Plattner VE, Gabor F. Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 2009; 6:727-44. [DOI: 10.1517/17425240903022758] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
72
|
Fries P, Wirth M, Seidel R, Bücker A, Schneider G. Differenzialdiagnose ovarieller Raumforderungen in der MRT. ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1221794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
73
|
Seidel R, Dabew ER, Zwick C, Wirth M, Bücker A. Evaluierung der HRCT bei immunsuppremierten Patienten mit Verdacht auf pulmonale Pilzinfektion. ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1221587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
74
|
Seidel R, Wirth M, Dabew ER, Opitz A, Bücker A. CT Angiographie zur Detektion akuter pulmonaler Embolien im Kontext typischer und atypischer klinischer Präsentation. ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1221766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
75
|
Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol 2009; 40:27-30. [PMID: 19177318 DOI: 10.1055/s-0028-1098786] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
With the introduction of targeted therapies, a paradigm shift for the treatment of metastatic renal cell cancer has taken place. New compounds like sunitinib, sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards. An interdisciplinary consensus conference was held to discuss treatment sequences and open questions. Results from the 2007 conference provided the basis for the 2008 meeting. The results of the 2008 conference are presented as short theses.
Collapse
|